AU2013326974B2 - Methods of quantitating heavy and light chain polypeptide pairs - Google Patents

Methods of quantitating heavy and light chain polypeptide pairs Download PDF

Info

Publication number
AU2013326974B2
AU2013326974B2 AU2013326974A AU2013326974A AU2013326974B2 AU 2013326974 B2 AU2013326974 B2 AU 2013326974B2 AU 2013326974 A AU2013326974 A AU 2013326974A AU 2013326974 A AU2013326974 A AU 2013326974A AU 2013326974 B2 AU2013326974 B2 AU 2013326974B2
Authority
AU
Australia
Prior art keywords
heavy chain
light chain
chain polypeptide
polypeptide
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013326974A
Other languages
English (en)
Other versions
AU2013326974A1 (en
Inventor
Jason Baardsnes
Yang-Chieh CHOU
Adam Louis CORPER
Gordon Yiu Kon Ng
Maureen O'connor-Mccourt
Anders Ohrn
Antonios SAMIOTAKIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymeworks BC Inc
Original Assignee
Zymeworks BC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymeworks BC Inc filed Critical Zymeworks BC Inc
Publication of AU2013326974A1 publication Critical patent/AU2013326974A1/en
Assigned to ZYMEWORKS INC., NATIONAL RESEARCH COUNCIL CANADA (NRC) reassignment ZYMEWORKS INC. Request for Assignment Assignors: BAARDSNES, JASON, NATIONAL RESEARCH COUNCIL CANADA (NRC), O'CONNOR-MCCOURT, MAUREEN, ZYMEWORKS INC.
Assigned to ZYMEWORKS INC., NATIONAL RESEARCH COUNCIL OF CANADA reassignment ZYMEWORKS INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: NATIONAL RESEARCH COUNCIL OF CANADA (NRC), ZYMEWORKS INC.
Application granted granted Critical
Publication of AU2013326974B2 publication Critical patent/AU2013326974B2/en
Assigned to ZYMEWORKS INC. reassignment ZYMEWORKS INC. Request for Assignment Assignors: NATIONAL RESEARCH COUNCIL OF CANADA, ZYMEWORKS INC.
Assigned to ZYMEWORKS BC INC. reassignment ZYMEWORKS BC INC. Request to Amend Deed and Register Assignors: ZYMEWORKS INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2013326974A 2012-10-03 2013-10-03 Methods of quantitating heavy and light chain polypeptide pairs Active AU2013326974B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261744911P 2012-10-03 2012-10-03
US61/744,911 2012-10-03
PCT/US2013/063306 WO2014055784A1 (en) 2012-10-03 2013-10-03 Methods of quantitating heavy and light chain polypeptide pairs

Publications (2)

Publication Number Publication Date
AU2013326974A1 AU2013326974A1 (en) 2015-05-21
AU2013326974B2 true AU2013326974B2 (en) 2019-01-03

Family

ID=50435442

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013326974A Active AU2013326974B2 (en) 2012-10-03 2013-10-03 Methods of quantitating heavy and light chain polypeptide pairs

Country Status (7)

Country Link
US (1) US9771573B2 (https=)
EP (1) EP2904093B1 (https=)
JP (1) JP6581505B2 (https=)
CN (1) CN105121630B (https=)
AU (1) AU2013326974B2 (https=)
CA (1) CA2886422C (https=)
WO (1) WO2014055784A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
BR112014010580B1 (pt) 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
CN105026430B (zh) 2012-11-28 2025-03-25 酵活英属哥伦比亚有限公司 工程化免疫球蛋白重链-轻链对及其用途
CA3244731A1 (en) 2014-05-28 2025-11-29 Zymeworks Bc Inc. Modified antigen binding polypeptide constructs and uses thereof
WO2016172485A2 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
WO2017055404A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
JP6734919B2 (ja) * 2015-10-02 2020-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 同時結合を測定するための細胞ベースのｆｒｅｔアッセイ法
EP3359576B1 (en) 2015-10-08 2024-12-25 Zymeworks BC Inc. Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
MY201482A (en) 2017-04-03 2024-02-26 Hoffmann La Roche Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
EP4516809A3 (en) 2017-04-05 2025-09-03 F. Hoffmann-La Roche AG Bispecific antibodies specifically binding to pd1 and lag3
JOP20190222A1 (ar) 2017-04-11 2019-09-24 Zymeworks Inc الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3
EP3630836A1 (en) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
AR112603A1 (es) 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765516A2 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
EP3927431A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP3927746A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
JP7737306B2 (ja) 2019-02-21 2025-09-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CN115843312A (zh) 2020-04-24 2023-03-24 马伦戈治疗公司 结合至t细胞相关癌细胞的多功能性分子及其用途
GB2616354A (en) 2020-08-26 2023-09-06 Marengo Therapeutics Inc Methods of detecting TRBC1 or TRBC2
AU2021331075A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
GB2616128A (en) 2020-08-26 2023-08-30 Marengo Therapeutics Inc Antibody molecules that bind to NKp30 and uses thereof
US20230374162A1 (en) * 2020-10-07 2023-11-23 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
CA2403739A1 (en) 2000-03-15 2001-09-20 Heska Corporation Three-dimensional model of a complex between a fc epsilon receptor alpha chain and a fc region of an ige antibody and uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20030082630A1 (en) 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
AU2002353018A1 (en) * 2001-12-03 2003-06-17 Dyax Corporation Library screening
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US8150634B1 (en) * 2004-11-12 2012-04-03 Bristol-Myers Squibb Company Protein-ligand NOE matching for high-throughput structure determination
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
US20090148905A1 (en) 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
US9266967B2 (en) * 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) * 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
US20100075326A1 (en) 2008-09-12 2010-03-25 Cornell University Yeast surface two-hybrid system for quantitative detection of protein-protein interactions
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
EP2417164A1 (en) 2009-04-07 2012-02-15 Roche Glycart AG Bispecific anti-erbb-2/anti-c-met antibodies
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP4012714A1 (en) 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
CN102153650B (zh) * 2011-01-27 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 一种抗egfr人源化抗体l2-h3及其编码基因与应用
BR112013023918A2 (pt) 2011-03-25 2016-12-13 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
EP2726504A1 (en) 2011-05-27 2014-05-07 Dutalys Antibodies with improved folding stability
CN109134658B (zh) 2011-10-31 2022-10-14 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
BR112014010580B1 (pt) 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
AU2013258834B2 (en) 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
CN105026430B (zh) 2012-11-28 2025-03-25 酵活英属哥伦比亚有限公司 工程化免疫球蛋白重链-轻链对及其用途
ES2821753T3 (es) 2013-03-15 2021-04-27 Lilly Co Eli Procedimientos de producción de Fab y de anticuerpos biespecíficos
CA3244731A1 (en) 2014-05-28 2025-11-29 Zymeworks Bc Inc. Modified antigen binding polypeptide constructs and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHLATTER, S ET AL., BIOTECHNOLOGY PROGRESS., (2005-01), vol. 21, no. 1, pages 122 - 133 *

Also Published As

Publication number Publication date
EP2904093B1 (en) 2019-04-10
JP2015533089A (ja) 2015-11-19
CN105121630B (zh) 2018-09-25
CA2886422A1 (en) 2014-04-10
EP2904093A4 (en) 2016-06-08
WO2014055784A1 (en) 2014-04-10
EP2904093A1 (en) 2015-08-12
US9771573B2 (en) 2017-09-26
JP6581505B2 (ja) 2019-09-25
US20150211001A1 (en) 2015-07-30
AU2013326974A1 (en) 2015-05-21
CA2886422C (en) 2022-12-13
CN105121630A (zh) 2015-12-02

Similar Documents

Publication Publication Date Title
AU2013326974B2 (en) Methods of quantitating heavy and light chain polypeptide pairs
JP7761704B2 (ja) 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
JP6602884B2 (ja) ビタミンｄの測定法
JP2023524041A (ja) Ｋｒａｓ特異的抗体及びその使用
EP2785740A1 (en) Anti-glucagon antibodies and uses thereof
US20210047431A1 (en) Anti-pla2-gib antibodies and the uses thereof
JP2023524062A (ja) 治療用タンパク質に対する中和抗体アッセイ
US12043669B2 (en) IL-1 receptor accessory protein-inhibiting antibodies and antigen-binding fragments thereof
JP7829590B2 (ja) 複雑な多段階の抗体相互作用を解明するための方法
KR20210093961A (ko) Amh에 대해 특이적인 항체 및 이의 용도
CN111936522A (zh) 新型抗胸苷激酶抗体
WO2025118037A1 (en) Binding proteins and methods and uses thereof
CN117285637B (zh) 一种抗独特型抗体及其应用
US20070161089A1 (en) Method of Producing Pan-Specific Antibodies
WO2025209553A1 (en) System and method for detecting the interaction between reactive probes and proteins
US20260098866A1 (en) Taci antibody and use thereof
US20240117069A1 (en) Materials and Methods for Monitoring Cancer by Administering an Anti-MCL1 Antibody
WO2026022157A1 (en) Anti-gastrin antibodies and uses thereof
KR20190020806A (ko) 면역글로불린 단일 가변 도메인에 대한 개선된 약동학적 어세이
WO2026025029A1 (en) Method for selectively controlling the generation of degradants from a biological product exposed to a stress condition
CN108727493B (zh) 抗Stathmin单克隆抗体及其用途
CN118852422A (zh) I型前胶原n末端前肽特异性抗体、试剂盒和用途
HK1184470A1 (zh) 抗人igg1抗体

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ZYMEWORKS INC.; NATIONAL RESEARCH COUNCIL CANADA (

Free format text: FORMER APPLICANT(S): BAARDSNES, JASON; O'CONNOR-MCCOURT, MAUREEN; ZYMEWORKS INC.; NATIONAL RESEARCH COUNCIL CANADA (NRC)

TH Corrigenda

Free format text: IN VOL 29 , NO 38 , PAGE(S) 5763 UNDER THE HEADING ASSIGNMENTS BEFORE GRANT, SECTION 113 - 2013 UNDER THE NAME ZYMEWORKS INC.; NATIONAL RESEARCH COUNCIL CANADA (NRC), APPLICATION NO. 2013326974, UNDER INID (71) CORRECT THE CO-APPLICANT NAME TO ZYMEWORKS INC.; NATIONAL RESEARCH COUNCIL OF CANADA (NRC)

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ZYMEWORKS INC.

Free format text: FORMER OWNER(S): ZYMEWORKS INC.; NATIONAL RESEARCH COUNCIL OF CANADA

HB Alteration of name in register

Owner name: ZYMEWORKS BC INC.

Free format text: FORMER NAME(S): ZYMEWORKS INC.